You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,365,634


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,365,634
Title:Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
Abstract: Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB.
Inventor(s): Beliveau; Richard (Montreal, CA), Demeule; Michel (Beaconsfield, CA), Che; Christian (Montreal, CA), Regina; Anthony (Montreal, CA)
Assignee: Angiochem Inc. (Montreal, CA)
Application Number:12/601,803
Patent Claims:1. A polypeptide comprising an amino acid sequence having the amino acid sequence of Angiopep-7 (SEQ ID NO: 112) wherein said polypeptide is transported to at least one cell or tissue selected from the group consisting of liver, lung, kidney, spleen, and muscle.

2. The polypeptide of claim 1, wherein said polypeptide consists of the amino acid sequence of Angiopep-7 (SEQ ID NO: 112).

3. A composition comprising the polypeptide of claim 1.

4. The composition of claim 3 comprising a pharmaceutically acceptable carrier.

5. A conjugate comprising: (a) a vector comprising a polypeptide of claim 1; and (b) a therapeutic agent, diagnostic agent, or detectable label, wherein said agent or label is conjugated to said vector.

6. The conjugate of claim 5, wherein said vector consists of a polypeptide consisting of the amino acid sequence of Angiopep-7 (SEQ ID NO:112).

7. The conjugate of claim 5, wherein said vector is conjugated to a therapeutic agent.

8. The conjugate of claim 5, wherein said therapeutic agent is an anticancer agent.

9. The conjugate of claim 8, wherein said anticancer agent is selected from the group consisting of abarelix, aldesleukin, alitertinoin, allopurinol, altretamine, amifostine, anakinra, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bexarotene, bleomycin, bortezomib, busulfan, calusterone, capecitabine, carboplatin, carmustine, zoledronic, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, actinomycin D, dalteparin, darbepoetin alfa, dasatinib, daunorubicin, daunomycin, decitabine, denileukin, Denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, epirubicin, epoetin alfa, erlotinib, estramustine, etoposide, exemestane, fentanyl, filgrastim, floxuridine, fludarabine, fluorouracil, 5-FU, fulvestrant, gefitinib, gemcitabine, goserelin, histrelin, hydroxyurea, idarubicin, ifosfamide, imatinib, Interferon alfa-2b, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide, levamisole, lomustine, CCNU, meclorethamine (nitrogen mustard), megestrol, melphalan (L-PAM), mercaptopurine (6-MP), mesna, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, oprelvekin, oxaliplatin, paclitaxel, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, peginterferon alfa-2b, pemeterxed, pentostatin, pipobroman, plicamycin (mithramycin), porfimer, procarbazine, quinacrine, rasburicase, sargramostim, sorafenib, streptozocin, sunitinib, sunitinib maleate, talc, tamoxifen, temozolomide, teniposide (VM-26), testolactone, thalidomide, thioguanine (6-TG), thiotepa, thiotepa, thiotepa, topotecan, toremifene, tretinoin (ATRA), uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, zoledronate, and zoledronic acid.

10. The conjugate of claim 9, wherein said agent is paclitaxel.

11. The conjugate of claim 5, wherein said vector is not efficiently transported across the BBB.

12. The conjugate of claim 5, wherein said conjugate accumulates more rapidly, accumulates to a higher concentration, exhibits reduced P-gp mediated efflux in a liver, lung, kidney, or spleen cell, as compared to said agent or label when not conjugated to said vector.

13. A composition comprising the conjugate of claim 5 and a pharmaceutically acceptable carrier.

Details for Patent 9,365,634

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2027-05-29
Merck Teknika Llc TICE BCG bcg live For Injection 102821 06/21/1989 ⤷  Try a Trial 2027-05-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2027-05-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2027-05-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2027-05-29
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 06/01/1989 ⤷  Try a Trial 2027-05-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.